309 related articles for article (PubMed ID: 12935890)
1. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
2. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.
Tamamura H; Fujisawa M; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2004 Jul; 569(1-3):99-104. PubMed ID: 15225616
[TBL] [Abstract][Full Text] [Related]
3. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
5. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
6. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
Kang H; Mansel RE; Jiang WG
Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
[TBL] [Abstract][Full Text] [Related]
7. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
[TBL] [Abstract][Full Text] [Related]
8. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
9. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo.
Mellor P; Harvey JR; Murphy KJ; Pye D; O'Boyle G; Lennard TW; Kirby JA; Ali S
Br J Cancer; 2007 Sep; 97(6):761-8. PubMed ID: 17726466
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of CXCR4 affect the migration and fate of CXCR4+ progenitors in the developing limb of chick embryos.
Yusuf F; Rehimi R; Moroşan-Puopolo G; Dai F; Zhang X; Brand-Saberi B
Dev Dyn; 2006 Nov; 235(11):3007-15. PubMed ID: 16958136
[TBL] [Abstract][Full Text] [Related]
11. Involvement of chemokine receptors in breast cancer metastasis.
Müller A; Homey B; Soto H; Ge N; Catron D; Buchanan ME; McClanahan T; Murphy E; Yuan W; Wagner SN; Barrera JL; Mohar A; Verástegui E; Zlotnik A
Nature; 2001 Mar; 410(6824):50-6. PubMed ID: 11242036
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer.
Liang AL; Qian HL; Zhang TT; Zhou N; Wang HJ; Men XT; Qi W; Zhang PP; Fu M; Liang X; Lin C; Liu YJ
Drug Des Devel Ther; 2015; 9():5671-86. PubMed ID: 26527862
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer.
Mori T; Doi R; Koizumi M; Toyoda E; Ito D; Kami K; Masui T; Fujimoto K; Tamamura H; Hiramatsu K; Fujii N; Imamura M
Mol Cancer Ther; 2004 Jan; 3(1):29-37. PubMed ID: 14749473
[TBL] [Abstract][Full Text] [Related]
14. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
15. Transendothelial migration of two metastatic breast carcinoma cells depend on the SDF-lalpha-CXCR4 complexes.
Lechertier T; Berard M; Vassy R; Herve MA; Crepin M
Anticancer Res; 2004; 24(6):4011-7. PubMed ID: 15739262
[TBL] [Abstract][Full Text] [Related]
16. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Tsutsumi H; Masuno H; Fujii N
Curr Med Chem; 2007; 14(1):93-102. PubMed ID: 17266570
[TBL] [Abstract][Full Text] [Related]
17. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
18. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.
Murakami T; Maki W; Cardones AR; Fang H; Tun Kyi A; Nestle FO; Hwang ST
Cancer Res; 2002 Dec; 62(24):7328-34. PubMed ID: 12499276
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha.
Salcedo R; Wasserman K; Young HA; Grimm MC; Howard OM; Anver MR; Kleinman HK; Murphy WJ; Oppenheim JJ
Am J Pathol; 1999 Apr; 154(4):1125-35. PubMed ID: 10233851
[TBL] [Abstract][Full Text] [Related]
20. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]